single20MG
Cartalax
20MG Protocol
Cartalax 20MG
Injection Freq.
Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
May support fibroblast/chondrocyte proliferation signals (Ki-67) in cell models
Sirtuin upregulation signals and reduced pro-apoptotic markers (p53/caspase-3) described
MMP-9 inhibition signals supporting extracellular-matrix homeostasis
Collagen-related cartilage integrity rationale (sequence-motif link)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 2,000 mcg (2.0 mg) | 30 |
| 2 | Weeks 3–4 | 3,000 mcg (3.0 mg) | 45 |
| 3 | Weeks 5–8 | 4,000 mcg (4.0 mg) | 60 |
| 4 | Weeks 9–12 | 5,000 mcg (5.0 mg) | 75 |
Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance
8–12 weeks; optional extension to 16 weeks
Cartalax (Ala–Glu–Asp) is presented as an ultrashort Khavinson-class bioregulatory peptide with proposed gene-regulatory activity at low concentrations. The protocol links Cartalax’s sequence to a motif found in type XI collagen, a structural protein relevant to cartilage integrity, and frames the peptide as a potential cartilage-support bioregulator. In preclinical fibroblast and chondrocyte culture studies summarized on the page, Cartalax is reported to increase Ki-67 (a proliferation marker) and to increase sirtuin (SIRT-1/SIRT-6) expression while reducing p53 and caspase-3 activity (pro-apoptotic signaling). The page also cites inhibition of MMP-9 synthesis, an enzyme associated with extracellular-matrix degradation, which is positioned as supportive of matrix homeostasis. Overall, Cartalax is framed as influencing cell survival, proliferation, and matrix-remodeling programs via epigenetic/gene-expression regulation; the protocol notes that large human RCT evidence is not available.
Mild injection-site reactions (redness/itching)
Limited evidence base (primarily in vitro/rodent data
no large human RCTs described)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)